Plain-English translation of NCT06233461 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Crohn's Disease research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new oral medication called to see if it can reduce inflammation in the bowel and help people with moderate to severe Crohn's disease feel better. About 268 people will participate worldwide. Some participants will receive the medication at different doses, while others will receive a placebo (a pill with no active medicine) so researchers can compare results fairly.
Many people with Crohn's disease don't respond well enough to current treatments, or they lose the benefit over time. This medication is being tested to offer a new option for people whose disease isn't controlled by existing therapies.
You likely qualify if…
You likely don't qualify if…
You will visit the study center multiple times over about 60 weeks (roughly 14 months). You'll be randomly assigned to take either the new medication at one of three different doses or a placebo as an oral capsule. The study team will monitor your health, symptoms, and bowel inflammation throughout the trial and during a 4-week follow-up period after treatment ends. You'll have regular check-ins with doctors to track how you're doing and watch for any side effects.
AI-generated summary from trial data · Jul 7, 2026 · Not medical advice
United States